Back to Search
Start Over
Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection
- Source :
- Revue Neurologique
- Publication Year :
- 2021
- Publisher :
- Elsevier Masson SAS., 2021.
-
Abstract
- OBJECTIVE: To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection. METHODS: We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups. RESULTS: In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58-28.6], 16.5 [16.3-48.5], 1116 [434-1747] and 1272 [658-1886], respectively, P
- Subjects :
- COVID-19 Vaccines
medicine.drug_class
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Disease
Monoclonal antibody
Serology
Multiple sclerosis
03 medical and health sciences
0302 clinical medicine
Clinical endpoint
medicine
Humans
030212 general & internal medicine
Humoral response
Antibody
biology
business.industry
SARS-CoV-2
Vaccination
COVID-19
medicine.disease
Neurology
Immunology
biology.protein
Original Article
Neurology (clinical)
business
Vaccine
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 00353787
- Database :
- OpenAIRE
- Journal :
- Revue Neurologique
- Accession number :
- edsair.doi.dedup.....04d416fb130c6bd7f9ff32fbcef5883c